Targeted therapy with trastuzumab deruxtecan shows improved overall survival compared to standard chemotherapy in patients with HER2-amplified metastatic colorectal cancer.
← News
Science Breakthroughs Science Breakthroughs Knowledge
AACR 2026: Real-World Data Show Targeted Therapy Extends Survival in Aggressive Form of Colorectal Cancer | Newswise
Trastuzumab Deruxtecan Vs Standard Chemotherapy Treatment approach
HER2-Amplified MSS Metastatic Colorectal Cancer Cancer type
AACR 2026 Conference
Dr. Zunairah Shah, MBBS Lead researcher